Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody

Molecular Cancer Therapeutics

Volumn 12, Issue 10, 2013, Pages 2043-2054

  Song, Hong ^a   Hedayati, Mohammad ^a   Hobbs, Robert F ^a   Shao, Chunbo ^a   Bruchertseifer, Frank ^c   Morgenstern, Alfred ^c   DeWeese, Theodore L ^a,b   Sgouros, George ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOINT RESEARCH CENTRE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB BI 213; DNA DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GAMMA HISTONE H2AX; HISTONE H2AX; NU 7441; PROGESTERONE RECEPTOR; PROTEIN KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER SUSCEPTIBILITY; COMET ASSAY; CONTROLLED STUDY; DNA END JOINING REPAIR; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG TARGETING; GENE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER;

ALPHA PARTICLES; ANTIBODIES, MONOCLONAL, HUMANIZED; BISMUTH; BRCA1 PROTEIN; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA END-JOINING REPAIR; DNA REPAIR; FEMALE; HISTONES; HUMANS; RADIOISOTOPES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84885675997     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0108     Document Type: Article

References (53)

1. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43: 693-713.
2. Song H, Sgouros G. Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv 2011;8: 26-44.
3. Pai-Scherf LH, Carrasquillo JA, Paik C, Gansow O, Whatley M, Pearson D, et al. Imaging and phase I study of 111In- and 90Y-labeled anti- LewisY monoclonal antibody B3. Clin Cancer Res 2000;6: 1720-30.
4. Sharkey RM, Goldenberg DM, Murthy S, Pinsky H, Vagg R, Pawlyk D, et al. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic- antigen-specific, murine monoclonal antibody, MN- 14. Cancer 1993;71: 2082-96.
5. Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, et al. Alpha-particle emitting atomic generator (Actinium-225)- labeled trastuzumab (Herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res 2004;10: 4489-97.
6. Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, et al. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res 2001;61: 2008-14.
7. Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panageas KS, et al. Patient-specific, 3-dimensional dosimetry in non- Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med 2003;44: 260-8.
8. Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol 2003;30: 6-10.
9. Johansson L, Carlsson J, Nilsson K. Radiosensitivity of human Blymphocytic lymphomas in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 1982;41: 411-20.
10. M'Kacher R, Bennaceur A, Farace F, Lauge A, Plassa LF, Wittmer E, et al. Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma. Oncogene 2003;22: 7905-12.
11. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012;481: 287-94.
12. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007;7: 937-48.
13. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68: 700-10.
14. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56: 5360-4.
15. Lynch HT, de la Chapelle A. Hereditary colorectal cancer.NEngl J Med 2003;348: 919-32.
16. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair geneMGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343: 1350-4.
17. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25: 1341-51.
18. Kasparek TR, Humphrey TC. DNA double-strand break repair pathways, chromosomal rearrangements and cancer. Semin Cell Dev Biol 2011;22: 886-97.
19. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
20. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13: 4429-34.
21. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, et al. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triplenegative breast cancer. Clin Cancer Res 2010;16: 4702-10.
22. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10: 515-27.
23. Song H, Shahverdi K, Huso DL, Esaias C, Fox J, Liedy A, et al. 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res 2008;68: 3873-80.
24. Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res 2009;69: 8941-8.
25. Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem 2005;77: 6288-91.
26. Zielinska B, Apostolidis C, Bruchertseifer F, Morgenstern A. An improved method for the production of Ac-225/Bi-213 from Th-229 for targeted alpha therapy. Solvent Extr Ion Exc 2007;25: 339-49.
27. McDevitt MR, Finn RD, Sgouros G, Ma D, Scheinberg DA. An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation. Appl Radiat Isot 1999;50: 895-904.
28. Song H, Shahverdi K, Huso DL, Wang Y, Fox JJ, Hobbs RF, et al. An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer. Clin Cancer Res 2008;14: 6116-24.
29. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006;66: 5354-62.
30. Sgouros G, Ballangrud ÅM, Humm JL, Jurcic JG, McDevitt MR, Erdi YE, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999;40: 1935-46.
31. Howell RW, Rao DV, Bouchet LG, Bolch WE, Goddu SM. MIRD cellular S values. Reston, VA: Society of Nuclear Medicine; 1997.
32. Hamacher KA, Den RB, Den EI, Sgouros G. Cellular dose conversion factors for alpha-particle-emitting radionuclides of interest in radionuclide therapy. J Nucl Med 2001;42: 1216-21.
33. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 2010;16: 5303-11.
34. Andersson H, Cederkrantz E, Back T, Divgi C, Elgqvist J, Himmelman J, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F (ab')2-a phase I study. J Nucl Med 2009;50: 1153-60.
35. Allen BJ, Singla AA, Rizvi SM, Graham P, Bruchertseifer F, Apostolidis C, et al. Analysis of patient survival in a Phase I trial of systemic targeted alpha-therapy for metastatic melanoma. Immunotherapy 2011;3: 1041-50.
36. Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari A, Hofer S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acidsubstance p. Clin Cancer Res 2006;12: 3843-50.
37. Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8: 587-94.
38. Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, et al. PET imaging of HER1-expressing xenografts in mice with 86YCHX- A00-DTPA-cetuximab. Eur J Nucl Med Mol Imaging 2010;37: 1368-76.
39. Nayak TK, Garmestani K, Milenic DE, Brechbiel MW. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med 2012;53: 113-20.
40. Schechter NR, Wendt RE III, Yang DJ, Azhdarinia A, Erwin WD, Stachowiak AM, et al. Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2004;45: 1683-7.
41. Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, et al. Intravesical alpha-radioimmunotherapy with 213Bi-anti- EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med 2009;50: 1700-8.
42. Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, et al. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 2008;23: 619-31.
43. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360: 1408-17.
44. Wygoda Z, Kula D, Bierzynska-Macyszyn G, Larysz D, Jarzab M, Wlaszczuk P, et al. Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. Hybridoma 2006;25: 125-32.
45. Nieuwenhuis B, Van Assen-Bolt AJ, Van Waarde-Verhagen MA, Sijmons RH, Van der Hout AH, Bauch T, et al. BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage. Int J Radiat Biol 2002;78: 285-95.
46. Andreassen CN, Alsner J. Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother Oncol 2009;92: 299-309.
47. Karlsson KH, Stenerlow B. Focus formation of DNA repair proteins in normal and repair-deficient cells irradiated with high-LET ions. Radiat Res 2004;161: 517-27.
48. Kinashi Y, Takahashi S, Kashino G, Okayasu R,Masunaga S, Suzuki M, et al. DNA double-strand break induction in Ku80-deficient CHO cells following Boron Neutron Capture Reaction. Radiat Oncol 2011;6:106.
49. Pessetto ZY, Yan Y, Bessho T, Natarajan A. Inhibition of BRCT (BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Breast Cancer Res Treat 2012; 134: 511-7.
50. Huang F, Motlekar NA, Burgwin CM, Napper AD, Diamond SL, Mazin AV. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. Acs Chem Biol 2011;6: 628-35.
51. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364: 205-14.
52. O'Shaughnessy J, Schwartzberg LS, Danso MA, Rugo HS, Miller K, Yardley R, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triplenegative breast cancer (TNBC). J Clin Oncol 2011;29:S1007.
53. Billecke CA, Ljungman ME, McKay BC, Rehemtulla A, Taneja N, Ethier SP. Lack of functional pRb results in attenuated recovery of mRNA synthesis and increased apoptosis following UV radiation in human breast cancer cells. Oncogene 2002;21: 4481-9.